The Hague-based Micreos, a Dutch/Swiss biotech company, announced on Tuesday, October 25, that it has secured €25M in growth funding in a fresh round.
The company will use the funds to invest in its specialised skincare brand, Gladskin, for people suffering from inflammatory skin conditions such as acne, eczema, and rosacea. Micreos claims that it has helped thousands of people in Europe and the USA.
Gladskin is based in the Netherlands with offices in the USA, Germany, France, and the UK.
The company will deploy the funds toward its pharmaceutical programmes, including the clinical development of endolysins against staphylococci (including MRSA) for Bloodstream Infections, Atopic Dermatitis, Diabetic Foot Ulcers, and Cutaneous T-cell Lymphoma.
The announcement comes over an year after raising €32M in a fresh round of funding. A few days back the company announced the appointment of the company’s antimicrobial vector engineering team, Dr. Matthew Dunne, Dr. Samuel Kilcher, and Dr. Anja Keller, who joined them from the Swiss Federal Institute of Technology (ETH Zurich).
The trio will be responsible for developing synthetic precision antimicrobials for medical indications across infectious and inflammatory diseases.
Micreos: What you need to know
Led by CEO Mark Offerhaus, Micreos develops targeted antibacterial solutions based on endolysin- and phage technology as a sustainable alternative to antibiotics.
Endolysins are naturally occurring enzymes that can target only harmful bacteria while preserving the beneficial ones that form an important part of our natural defence, often referred to as our microbiome. Endolysins are safe and environmentally friendly, says the company.
The company claims to have pioneered the development of this technology and brought the world the first endolysin-based precision antibacterials.
Offerhaus says, “With this restructuring, we align business and market requirements, enabling each business to pursue its growth strategy. It is especially important for the pharmaceutical business, which is capital-intensive and extremely promising. As a result, direct investments in Micreos Pharma, headed by Matt Regan, will now be possible.”
Apart from the group headquarters in The Hague, Micreos Pharmaceuticals has headquarters in Zug, Switzerland, a Discovery and Technology Centre in Wädenswil, Switzerland, and a Development Team in Bilthoven, the Netherlands.